Allergan plc does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg ratio.
Tag: AGN
Allergan PLC Valuation – May 2018 $AGN
Allergan plc Ordinary Shares does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, and the poor dividend history.
Allergan plc Valuation – January 2017 $AGN
Allergan plc Ordinary Shares does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, and the poor dividend history.
Allergan PLC Analysis – August 2015 Update $AGN
Allergan PLC does not qualify for either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability over the last ten years, lack of dividends, and the high PEmg and PB ratios.
34 Companies in the Spotlight This Week – 2/7/15
We evaluated 34 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. We also put each company through the ModernGraham valuation model based on Benjamin Graham’s value investing formulas in order to determine an intrinsic value for each. Here’s a summary of the ModernGraham Valuations.
Allergan Inc. Quarterly Valuation – February 2015 $AGN
Allergan Inc. is suitable for the Enterprising Investor but not for the Defensive Investor. The Defensive Investor is concerned by the insufficient earnings stability over the last ten years as well as the high PEmg and PB ratios.
27 Companies in the Spotlight This Week – 11/8/14
We evaluated 27 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. We also put each company through the ModernGraham valuation model based on Benjamin Graham’s value investing formulas in order to determine an intrinsic value for each. Here’s a summary of the ModernGraham Valuations.
Allergan Inc. Quarterly Valuation – November 2014 $AGN
At the initial phase of an analysis, Allergan appears suitable for the Enterprising Investor but not the Defensive Investor due to the lack of earnings stability over the last ten years, and the high PEmg and PB ratios.
19 Companies in the Spotlight This Week – 7/26/14
We evaluated 19 different companies this week to determine whether they are suitable for Defensive Investors, those unwilling to do substantial research, or Enterprising Investors, those who are willing to do such research. Here’s a summary of each company’s valuation.
Allergan Inc. Quarterly Valuation – July 2014 $AGN
Allergan Inc. is suitable for the Enterprising Investor but not the Defensive Investor. The Defensive Investor has concerns with the lack of earnings stability over the last ten years and the high PEmg and PB ratios.